Key result
Novel recombinant hERG cell line enables stable, reproducible screening for drug cardiotoxicity.
Why the study?
Early detection of drug-induced inhibition of hERG K+ channels is a major challenge in preclinical cardiotoxicity screening.
May aid preclinical cardiotoxicity screening; leaves open validation for routine high-throughput use.
Many drugs are cardiotoxic because they inhibit hERG K + channels, thus prolonging the repolarization phase of the cardiomyocyte action potential giving rise to cardiac arrhythmias. Early detection of inhibiting effects of candidate drugs on the activity of K + channels in cardiomyocytes is one of the main challenges in preclinical drug screening. The aim of this study was to obtain a cell line expressing recombinant hERG channels at a stable and reproducible level as a prerequisite to its further application as a test system.
No takes yet. Share an insight, caveat, or question.
Шутов et al. (2008) studied Drug cardiotoxicity. Cell line expressing recombinant hERG channels was evaluated on Development of a cell line expressing recombinant hERG channels at a stable and reproducible level. A cell line expressing recombinant hERG channels at a stable and reproducible level was developed for use as a preclinical test system for assaying drug cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: